The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.
 
Danielle Sara Bitterman
Employment - Agios (I); Agios (I); Agios (I); Agios (I); Massachusetts General Hospital Cancer Center; Massachusetts General Hospital Cancer Center; Massachusetts General Hospital Cancer Center; Massachusetts General Hospital Cancer Center
Stock and Other Ownership Interests - Agios (I); Agios (I); Agios (I); Agios (I)
 
Andrzej Niemierko
No Relationships to Disclose
 
Emily E. Van Seventer
No Relationships to Disclose
 
Daniel W. Kim
No Relationships to Disclose
 
Motaz Qadan
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Florence Keane
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Speakers' Bureau - OncLive; OncLive; OncLive; OncLive
 
Christine Elissa Eyler
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Driver, Inc; Driver, Inc; Driver, Inc; Eisai; Eisai; Eisai; Eisai; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; PureTech; PureTech; PureTech; PureTech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; FOGPharma; FOGPharma; FOGPharma; FOGPharma; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Genentech; Genentech; Genentech; Genentech; Loxo; Loxo; Loxo; Loxo; Merrimack; Merrimack; Merrimack; Merrimack; N-of-One; N-of-One; N-of-One; N-of-One; Novartis; Novartis; Novartis; Novartis; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines; Roche; Roche; Roche; Roche; Roivant; Roivant; Roivant; Roivant; Shionogi; Shionogi; Shionogi; Shionogi; Shire; Shire; Shire; Shire; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio
Research Funding - Asana Biosciences; Asana Biosciences; Asana Biosciences; Asana Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Sanofi; Sanofi; Sanofi; Sanofi
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)